It was a serious problem that was looking for a solution. Jilma read up a lot of scientific literature surveys and got to ...

Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biotechnology company with a market ...

Cases of secondary tumors have been reported as a possible adverse reaction to the treatment of certain blood cancers with CAR T-cells. A recent analysis of the cases reported to the ...

The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...

Andrew Young is an influential leader in the biotechnology sector, serving as the CEO and Managing Partner of Conjugate Group ...

Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...

Some of the most exclusive seats at President Donald Trump’s inauguration were reserved for powerful tech CEOs who also are among the world’s richest men.